Paradigm Biopharmaceuticals Limited (ASX:PAR) Insider Paul Rennie Buys 5,181,688 Shares of Stock

Paradigm Biopharmaceuticals Limited (ASX:PAR) insider Paul Rennie acquired 5,181,688 shares of the stock in a transaction on Tuesday, February 11th. The stock was bought at an average price of A$0.50 ($0.32) per share, with a total value of A$2,590,844.00 ($1,639,774.68).

Paradigm Biopharmaceuticals Price Performance

The stock has a market capitalization of $196.66 million, a PE ratio of -2.47 and a beta of 0.94. The company has a quick ratio of 5.93, a current ratio of 7.22 and a debt-to-equity ratio of 1.01.

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases.